JIANGXI FUSHINE PHARMACEUTICAL CO., LTD.

Jiangxi Fushine Pharmaceutical Co., Ltd.

300497

CNE1000024Z7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
11.34 ^CNY	-1.39%		-0.79%	+21.15%

28/04	Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
28/04	Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Jiangxi Fushine Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020

May 20, 2021 at 01:06 am IST

Jiangxi Fushine Pharmaceutical Co., Ltd. at its annual general meeting held on May 18, 2021 approved final cash dividend/10 shares (tax included) of CNY 2.00000000 for the year 2020.

Latest news about Jiangxi Fushine Pharmaceutical Co., Ltd.

Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28/04	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/04	CI
Fushine Pharma's Unit Gets Nod for Tazobactam Sodium	19/02	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding	04/12	CI
Fushine Pharmaceutical's Unit Gets Nod to Market Antidepressant	21/11	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/23/24	CI
Jiangxi Fuxiang Pharma to Invest 32.5 Million Yuan in New Biotechnology Unit	05/23/05	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Fuxiang Pharma's Profit to Rise in H1	12/23/12	MT
Fuxiang Pharma’s Vice Chairman, Deputy General Manager to Boost Shareholding	19/23/19	MT
Fushine Pharma Earmarks 386 Million Yuan to Build New Chemical Factory	23/23/23	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	25/23/25	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/22/26	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	03/22/03	CI
Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 4, 2021, has expired with 11,355,900 shares, representing 2.09% for CNY 174.83 million.	30/22/30	CI
LinkChem Co., Ltd. announced that it has received CNY 117 million in funding from Jiangxi Fushine Pharmaceutical Co., Ltd.	21/22/21	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	28/22/28	CI
LinkChem Co., Ltd. announced that it expects to receive CNY 117 million in funding from Jiangxi Fushine Pharmaceutical Co., Ltd.	18/22/18	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	01/22/01	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	05/22/05	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/21/26	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	11/21/11	CI

Chart Jiangxi Fushine Pharmaceutical Co., Ltd.

Duration

Period

Chart Jiangxi Fushine Pharmaceutical Co., Ltd.

More charts

Jiangxi Fushine Pharmaceutical Co., Ltd. is principally engaged in research and development, manufacturing and sales of bulk drugs, pharmaceutical intermediates and related products. The Company's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The Company distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.

Sector

Pharmaceuticals

Calendar

20/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGXI FUSHINE PHARMACEUTICAL CO., LTD.	+21.15%	85Cr
ELI LILLY AND COMPANY	+32.09%	69TCr
NOVO NORDISK A/S	+29.39%	58TCr
JOHNSON & JOHNSON	-1.34%	37TCr
MERCK & CO., INC.	+20.34%	33TCr
ABBVIE INC.	+7.39%	29TCr
ASTRAZENECA PLC	+14.25%	24TCr
ROCHE HOLDING AG	-3.03%	21TCr
NOVARTIS AG	+10.02%	21TCr
AMGEN INC.	+8.49%	17TCr

Other Pharmaceuticals